Lepu Medical announced that Shanghai Minwei Biotechnology Co., Ltd., a holding subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The MWN117 injection clinical trial application declared by Shanghai Minwei was approved, and it was agreed that this product could carry out clinical trials for overweight or obesity indications. MWN117 injection is a siRNA drug independently developed by Shanghai Minwei Biotech to target inHBE, and has global intellectual property rights. Non-clinical study results showed that in pharmacodynamics studies on spontaneously obese rhesus monkeys, MWN117 alone can significantly reduce animals' body fat rate and visceral fat while increasing muscle mass. The efficacy of a single injection lasts up to 12 weeks. Currently, no similar drugs have been approved for marketing at home or abroad.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.